The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11068 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial drugs

Open Access | Dose‐Dependent Risk of Neutropenia after 7‐Day Courses of Artesunate Monotherapy in Cambodian Patients with Acute Plasmodium falciparum Malaria

November 23, 2010 - 06:59 -- Kabogo Ndegwa
Author(s): 
Delia Bethell, Youry Se, Mark M. Fukuda, et al.
Reference: 
Clinical Infectious Diseases 15 December 2010, Vol. 51, No. 12:

Artesunate remains a crucial drug for the treatment of malaria, and determining optimal dosing regimens is vital to overcome emerging resistant parasite strains along the Thai‐Cambodian border.

Country: 
Medical Treatment: 

Pyrimethamine induces oxidative stress in Plasmodium yoelii 17XL-infected mice: A novel immunomodulatory mechanism of action for an old antimalarial drug?

September 10, 2010 - 13:23 -- Kabogo Ndegwa
Author(s): 
Martha Legorreta-Herrera, Raquel Retana-Ugalde, José Luis Ventura-Gallegos, Verónica Narváez
Reference: 
Experimental Parasitology, Volume 126, Issue 3, November 2010, Pages 381-388

Pyrimethamine is an antimalarial drug that has also been used successfully to treat autoimmune diseases such as lymphoproliferative syndrome. In this work, the effect of pyrimethamine (PYR) on the production of free radicals in malaria-infected mice was studied to better understand the drug’s immunomodulatory properties. BALB/c and CBA/Ca mice were infected with Plasmodium yoelii 17XL.

Medical Condition: 

Open Access | Glutathione Reductase-null Malaria Parasites Have Normal Blood Stage Growth but Arrest during Development in the Mosquito

August 25, 2010 - 08:48 -- Kabogo Ndegwa
Author(s): 
Rebecca Pastrana-Mena, Rhoel R. Dinglasan, Adelfa E. Serrano, et al
Reference: 
The Journal of Biological Chemistry, August 27, 2010, 285 27045-27056

Malaria parasites contain a complete glutathione (GSH) redox system, and several enzymes of this system are considered potential targets for antimalarial drugs.

Medical Treatment: 

Assessment of in vivo antimalarial activity of rifampicin, isoniazide, and ethambutol combination therapy

May 3, 2010 - 09:42 -- Kabogo Ndegwa
Author(s): 
Nayak P. Aditya, Swati Patankar and Basavaraj Madhusudhan
Reference: 
Parasitology Research, Volume 106, Number 6 / May, 2010

The existing armament of drugs for the treatment and prevention of malaria is inadequate due to development of resistance.

Medical Condition: 

The bisnaphthalimides as new active lead compounds against Plasmodium falciparum

April 29, 2010 - 12:55 -- Kabogo Ndegwa
Author(s): 
Maximilian Tischer, Ludmilla Sologub, Gabriele Pradel, Ulrike Holzgrabe
Reference: 
Bioorganic & Medicinal Chemistry, Volume 18, Issue 9, 1 May 2010, Pages 2998-3003

The bisquaternary bisnaphthalimides are a versatile class of compounds being active against the malaria parasite Plasmodium falciparum in the lower nanomolar range of concentration combined with no cytotoxicity.

Medical Condition: 

Letter: Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs

February 26, 2010 - 11:43 -- Kabogo Ndegwa
Author(s): 
Jianbing Mu, Rachel A Myers, Hongying Jiang, Shengfa Liu, Stacy Ricklefs, Michael Waisberg, Kesinee Chotivanich, Polrat Wilairatana, Srivicha Krudsood, Nicholas J White, et al.
Reference: 
Nature Genetics Volume: 42, Pages: 268–271, 2010

Here we report the first Plasmodium GWAS, which included 189 culture-adapted P. falciparum parasites genotyped using a custom-built Affymetrix molecular inversion probe 3K malaria panel array with a coverage of ~1 SNP per 7 kb.

Technology: 
Medical Condition: 
Medical Treatment: 

In Vitro Sensitivities of Plasmodium falciparum to Different Antimalarial Drugs in Uganda

February 25, 2010 - 13:51 -- Kabogo Ndegwa
Author(s): 
Samuel L. Nsobya, Moses Kiggundu, Sarah Nanyunja, Moses Joloba, Bryan Greenhouse, and Philip J. Rosenthal
Reference: 
Antimicrobial Agents and Chemotherapy, March 2010, Pages 1200-1206, Volume 54, No. 3

The control of malaria is challenged by resistance of Plasmodium falciparum to multiple drugs. New combination regimens are now advocated for the treatment of uncomplicated falciparum malaria, but the extent of resistance to newer agents is incompletely understood.

Technology: 
Country: 
Medical Treatment: 

In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea

February 11, 2010 - 13:36 -- Kabogo Ndegwa
Author(s): 
Rina P. M. Wong, Dulcie Lautu, Livingstone Tavul, Sara L. Hackett, Peter Siba, Harin A. Karunajeewa, Kenneth F. Ilett, Ivo Mueller, Timothy M. E. Davis
Reference: 
Tropical Medicine & International Health, Volume 15, Issue 3, March 2010, Pages: 342-349

To facilitate the monitoring of antimalarial drug resistance in this setting, we assessed the in vitro sensitivity of Plasmodium falciparum isolates from Madang Province.

Technology: 
Medical Condition: 
Medical Treatment: 

Minireview: Plasmodial heat shock proteins: targets for chemotherapy

January 10, 2010 - 16:46 -- Ingeborg van Schayk
Author(s): 
Addmore Shonhai
Reference: 
FEMS Immunology & Medical Microbiology, Early View (Articles online in advance of print)

Heat shock protein 90 (Hsp90), Hsp70/Hsp40 partnerships and small heat shock proteins are major malaria drug targets. This review examines the structural and functional features of these proteins that render them ideal drug targets and the challenges of targeting these proteins towards malaria drug design.

Medical Treatment: 

Pages

Subscribe to RSS - antimalarial drugs